Eride Quarta obtained MSc in Pharmaceutical Chemistry and Technology in 2017 and is currently a final year PhD student in Drugs, Biomolecules and Health Products at Food and Drug Department, University of Parma and R&D Scientist at Plumestars SRL, Italy.
She was awarded for the Best Poster at European Federation for Pharmaceutical Sciences Annual Meeting in 2019 at Frankfurt (Germany) with the Abstract: “Pulmonary Administration of a Novel Insulin Powder in Comparison to Afrezza®”. She was awarded in 2018 a Travel grant for the 5th Workshop on Pulmonary Drug Delivery and 1st SimInhale Summer School at Trinity College, Dublin and in 2019 a Travel grant for the 5th International TB Meeting, Groningen (NL). She was also selected to participate in 2019 at Business Match USMAC US in Silicon Valley 2019 2nd Edition programme and in September 2020 at Talent Open Innovation PhD programme in Italy.
Her research activities are focused on the development and characterization of micro and nano systems through particle engineering technology, such as spray drying, lyophilization, crystallization and design and development of novel orphan medicines by repurposing known drugs in innovative drug delivery systems. Her PhD programme is part of the European project CUPIDO, within Horizon2020 program, which aims to develop an innovative inhalation therapy for cardiovascular diseases.
Eride has published 4 original papers in peer-review journals such as the Journal of Controlled Release and she presented her work in more than 10 international conferences as poster communications and three oral presentation. The latest at AAPS Annual Meeting 2019, San Antonio (TX) with the abstract: “Novel insulin inhalation powder: bioavailability in rats”. She has submitted a patent application on the Novel composite microparticulate powders embedding peptide or micro-RNA drug loaded nanoparticles to be inhaled. She has presented posters at DDL 2018 and 2019, and this will be her third participation and the first oral presentation at DDL Conference 2020.